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Abstract
Regulatory T cells (Tregs) are physiologically designed to prevent autoimmune disease and
maintain self-tolerance. In tumour microenvironments, their presence is related to a poor
prognosis, and they influence the therapeutic outcome due to their capacity to suppress the
immune response by cell-cell contact and to release immunosuppressive cytokines. In this
study, we demonstrate that Treg immunosuppressive activity can be modulated by the
cross-linking between the CD45RA expressed by Tregs and the C-type lectin MGL. This
specific interaction strongly decreases the im-munosuppressive activity of Tregs, restoring
the proliferative capacity of co-cultured T lymphocytes. This effect can be attributed to
changes in CD45RA and TCR signalling through the inhibition of Lck and inactivation of
Zap-70, an increase in the Foxp3methylation status and, ultimately, the reduced production
of suppressive cytokines. These results indicate a role of MGL as an immunomodulator
within the tumour microenvironment interfering with Treg functions, suggesting its possible
use in the design of anticancer vaccines.
Introduction
Regulatory T cells (Tregs) (CD4+CD25+FOXP3+) play an essential role in the control of the
immune response. They are crucial for maintaining peripheral tolerance and protection against
autoimmunity, but they can also modulate immunity to infections and tumours [1]. In cancer,
Tregs represent one of the main cellular subsets of the regulative network that are found in
tumour microenvironments and are shown to be responsible for the negative regulation that
occurs during antitumor immune responses [2]. This population exerts its regulatory activity
through cell-cell contact and by producing suppressive factors such as interleukin (IL)-10 and
Tumour Growth Factor (TGF)-ß. Several reports have shown that their presence in tumours is
strongly related to the stage of disease and influences the outcome of the disease and therapy
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[3]. So far, several Treg subpopulations have been described, according to the co-expression of
FOXP3 and CD45RA: CD45RA+FOXP3low cells are resting Tregs (rTregs), CD45RA−FOXP3high
are activated Tregs (aTregs) and IL-17-secreting CD45RA−FOXP3low are non-suppressive T
cells (non-Tregs) [4]. CD45RA is one of the isoforms of CD45, a receptor-like protein tyrosine
phosphatase expressed by all nucleated hemopoietic cells. CD45 represents the predominant
transmembrane tyrosine phosphatase in lymphocytes and is required for the efficient induction
of T cell receptor (TCR) signalling and activation [5]. In fact, CD45 dictates the switching of
phosphorylation between the negative (Y505) and positive (Y394) regulatory Y residues of lym-
phocyte-specific protein tyrosine kinase (Lck kinase). Lck is inactive when Y505 is phosphory-
lated, while phosphorylation in Y394 triggers TCR activation and T cell proliferation through
the Zeta-chain-associated protein kinase 70 (Zap-70) activation [6]. Among Treg subpopula-
tions, the CD45RA+subset, expanded in vitro, gives rise to homogeneous Treg cell lines able to
maintain FOXP3 expression and exhibit superior suppressive capacity [7,8]. The regulation of
CD45RA activity in human Treg cells is poorly studied. CD45 expressed by effector T cells has
been shown to recognise the macrophage galactose-type C-type lectin (MGL) through itsN-
acetylgalactosamine epitope (GalNAc), resulting in the negative regulation of T cells in terms of
their proliferation and death [9]. MGL is a C-type lectin receptor expressed by activated macro-
phages and dendritic cells (DCs), which binds and internalises α- or ß-GalNAc (or Tn) residues
ofN- and O-glycans carried by self and non-self glycoproteins and/or glycosphingolipids [10].
Recently, we have shown the high plasticity of MGL and its capacity to modulate the immune
response. MGL expressed by DCs mediates the binding and internalisation of tumour-associated
antigen-carrying GalNAc residues, resulting in antigen cross-processing [11] and the induction
of phenotypic and functional dendritic cell (DC) maturation [12]. In this work, we were chal-
lenged to verify whether the Treg subpopulation could also be affected by MGL engagement.
The results demonstrate that CD45RA-MGL cross-linking decreases immunosuppressive activ-
ity of Tregs by changing CD45RA and TCR signalling and increasing Foxp3methylation accom-
panied by a reduced production of suppressive cytokines.
Materials and Methods
Treg isolation
Treg cells were purified from the buffy coat of healthy donors that were obtained from the
Department of Haematology Sapienza University of Rome after informed consent, employing
the human CD4+ CD127low CD25+ Regulatory T Cells kit (Stemcell, Canada) according to
manufacturer's instruction. Briefly, CD4+ CD127low T cells were first pre-enriched from the
buffy coat, and then T cells expressing high levels of CD25 were positively selected using Easy-
Sep Human CD25 Positive Selection Kit (Stemcell). Blood donor selection and collection was
performed according to italian blood transfusion policy, regarding the signing of informed
consent in which the donor agrees that his/her blood donation discard product can be used
also for experimental research. Blood donations were anonymized.
Flow cytometry
Cell phenotype staining was performed using the following panel of mouse monoclonal anti-
bodies (MoAbs) anti-CD4-FITC, anti-CD25-PE, anti-CD45RA-PeCy5 and anti-FOXP3-A-
lexa647. For analysis of FOXP3, cells were first permeabilised with Human FOXP3 Buffer and
then incubated with anti-FOXP3-Alexa 647. MoAbs anti-IgG1-FITC, anti-IgG1-PE, anti-IgG1-
PeCy5 and anti-IgG1-Alexa647 were employed as isotype controls. All the MoAbs and reagents
were from Becton Dickinson (San Diego, CA, USA). Treg cells were incubated with MoAbs for
30 minutes (min) at room temperature (RT). After washing, at least 104 events were evaluated
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using a FACSCanto flow cytometer running FACSDiva data acquisition and analysis software
(Becton Dickinson).
Binding of rhMGL to Tregs and competition assay
The human recombinant MGL protein (rhMGL-Fc) was synthesised by GenScript USA Inc
(Piscataway, NJ, USA). It contains the extracellular portion of the human MGL (MGL396-476)
linked to the human Fc of IgG1. For binding, Tregs were incubated for 30 min on ice with
rhMGL-Fc (10 μg/ml) in a solution of 20 mM Tris-HCL, pH 7.4, 150 mMNaCl, 2 mMMgCl2,
1 mM CaCl2 and 0.5% BSA (Sigma Chemical Company, St. Louis, MO, USA). Cells were exten-
sively washed before any assay. To verify the binding of rhMGL to Treg, cells were stained with
an anti-human IgG1 Fc-FITC (Jackson ImmunoReasearch Laboratories, West Grove, PA,
USA). The binding was analysed by FACSCanto flow cytometer running FACSDiva data
acquisition and analysis software. (Becton Dickinson). To evaluate the specificity of MGL bind-
ing, rhMGL-Fc was pre-incubated for 30 min at RT with GalNAc (20 μg/ml) and then added
to Treg cells for 30 min on ice. Tregs alone were used as negative control.
Immunoprecipitation andWestern blot analysis
Immunoprecipitation was performed using the Immunoprecipitation Kit-–Dynabeads Protein
G (Invitrogen, Oslo, Norway) according to manufacturer's instruction. Briefly, 50 μL of Dyna-
beads-protein G was added to 10 μg of rhMGL-Fc in 200 μL of Ab Binding &Washing Buffer
for 20 min at RT. rhMGL-Fc coated beads were then washed and added to the cellular lysate of
Tregs for 16 h at 4°C. The receptor coated to the beads was magnetically isolated and eluted
using 20 μL of Elution Buffer. The concentration of eluted samples was evaluated using the
Bradford assay (BioRad, München, Germany).
Immunoprecipitated samples were subjected to 3–8% or 4–12% sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE), and the resolved proteins were transferred
electrophoretically to a nitrocellulose transfer membrane (Schleicher and Schuell, Dassel, Ger-
many). The unspecific sites were blocked with phosphate-buffered saline (PBS) + 5% BSA
(Sigma) overnight at 4°C. Nitrocellulose membrane was then incubated with anti-CD45RA
antibody [MEM-56] (1:100) (Abcam) and with rhMGL-Fc (2,5 μg/mL) overnight at 4°C fol-
lowed by peroxidase-conjugated goat anti-mouse IgG (H + L) and goat anti-human IgG, Fc
fragment antibodies (1:20,000) (Jackson ImmunoResearch Laboratories, Suffolk, UK), respec-
tively for 1 h at RT.
For the signal transduction experiments, Tregs were stimulated with rhMGL-Fc as
described above. Cells were washed and incubated at 37°C for 20 min. Tregs were then lysed
using the NP-40 solution (Biocompare) in the presence of phenylmethylsulfonyl fluoride
(1 mM, PMES) (Sigma) and protease inhibitors (1X) (Sigma). Proteins obtained were resolved
using 4–12% SDS-PAGE and transferred to nitrocellulose. After blocking, membranes were
incubated with rabbit anti-pLck (Tyr 505) (Cell Signaling Technologies, Boston, MA, USA)
(1:1000), rabbit anti-pLck (Tyr 394) (Santa Cruz, CA, USA) (1:1000), rabbit anti-Zap-70 (Cell
Signaling Technologies) (1:1000) and mouse anti-β-actin (Santa Cruz) (1:1000) antibodies, fol-
lowed by peroxidase-conjugated goat anti-rabbit or anti-mouse IgG (H+L) (Jackson Immu-
noResearch Laboratories) (1:20000). The protein bands were detected with Lite Ablot Extend
(Euroclone, Lugano, Switzerland) following the manufacturer’s instructions. The density of
protein bands was analyzed by Image J software and was calculated in terms of average inten-
sity of bands of each proteins per average intensity of bands of β-actin.
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Immunosuppression assay
CD4+ CD25- T and Treg cells stimulated with rhMGL-Fc, were cultured alone or co-cultured
(Tregs:CD4+ CD25- T cells, 1:5) with anti-CD3 (1 μg/ml, OKT3) (eBioscience) and anti-CD28
(1 μg/ml)(BioLegend) antibodies for 4 days at 37°C. CD4+ CD25- T cells was pre-treated with
CarboxyFluorescein Succinimidyl Ester (1 μM, CFSE) (Life Technologies) and cell proliferation
was monitored through progressive halving of fluorescence using FACSCanto flow cytometer.
All experiments were performed in triplicate wells. One hundred percent proliferation was
defined as the proliferation of CD4+ CD25- T cells alone.
ELISpot assay
PBMCs derived from buffy coat of healthy donors were co-cultured with K562 cells, pulsed
with HLAI-A2 restricted Flu peptide (GILGFVFTL) (10 μg/mL) (Proimmune, Oxford, UK) for
12 days in RPMI+10% FCS in presence of IL-2 (10 U/ml) and IL-15 (10ng/ml). Flu-enriched
CD8+ T cells were isolated employing the human microbeads CD8 (Miltenyi Biotech) and co-
cultured with autologous Tregs (+/- rhMGL-Fc) and/or mDCs pulsed with Flu peptide in the
anti-IFN-γ precoated (1:200; Pharmingen San Diego, CA, USA) ELISpot plates (Millipore,
Bedford, MA, USA) overnight at 4°C. Cytokine release was detected with biotinylated anti-
IFN-γ antibody (Pharmingen; 1:250, 2 hrs at RT) revealed with streptavidin-alkaline phospha-
tase (Pharmingen) (1:1000, 100 mL/well, 1 h at RT) and chromogen substrate (5-bromo-4-
chloro-3-indolylphosphate (BCIP)/nitroblue tetrazolium alkaline phosphatase substrate,
Sigma) (50 μL/well). Spots were counted using the ImmunoSpot Image Analyzer (Aelvis).
Foxp3methylation analysis
Tregs, before and after stimulation with rhMGL-Fc protein, were lysed using Genomic Lysis
Buffer (Zymo Research, Irvine, CA, USA) as indicated by the manufacturer’s instructions.
Extraction of genomic DNA and Foxp3methylation analysis was performed by EpigenDx, Inc
(Hopkinton, MA, USA) (Assay ID: ADS783FS2, Human Foxp3, TSDR region).
Intracellular staining
Tregs after CD45RA stimulation were cultured with anti-CD3 (1 μg/ml)(eBioscience) and anti-
CD28 (5 μg/ml) (BioLegend, San Diego, CA, USA) in presence of Brefeldin A (10 μg/ml)
(Sigma) for 48 h at 37°C. Cells were collected, fixed and permeabilised with 0,5% saponin solu-
tion (Sigma). Intracellular staining was carried out using anti-IL-10-PE (Becton Dickinson),
anti-IL-4-PeCy5.5 (Becton Dickinson), anti-IFN-γ-FITC (Becton Dickinson) and anti-IL-
17-APC (eBioscience) antibodies. Cells were acquired by FACSCanto flow cytometer and ana-
lysed by FACSDiva software.
Cell death analysis
Tregs were seeded in 96-well plates at a density of 105/well and were cultured for 48 h with or
without rhMGL-Fc (10 μg/ml) in the presence of anti-CD3 antibody (2,5 μg/ml) (eBioscience,
San Diego, CA, USA). Apoptotic cells were evaluated using FSC/SSC as well as annexin-
V-FITC (Becton Dickinson)/propidium iodide-PE (Becton Dickinson) cell staining.
RNA isolation and reverse transcriptase Real-Time PCR assays
RNA extraction was performed with ReliaPrep RNA Cell Miniprep System (Promega,
Madison, WI, USA) according to the manufacturer’s protocol. RNA (1 μg) was then converted
into single-strand cDNA using high-capacity cDNA reverse transcription kits (Applied
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Biosystems, Foster City, CA, USA). Real-time PCR was carried out in a final reaction volume
of 20 μl containing 25 ng cDNA, 10 μl TaqMan Universal Master Mix II (Applied Biosystems),
1 μl of each TaqMan Gene Expression assay (Applied Biosystems) (GATA3 Hs00231122_m1,
RORC Hs01076122_m1, TBX21 Hs00203436_m1, B2M Hs99999907_1, RLP0
Hs99999902_m1) and DEPC-treated H2O (BioLine, Taunton, MA, USA). After denaturation
at 95°C for 10 min, the samples were subjected to 40 cycles at 95°C for 15 sec and at 60°C for 1
min. All samples were analysed in triplicate using StepOne Real-Time PCR System (Life Tech-
nologies, USA). Gene expression levels were normalised using the 2-ΔΔCt method.
Statistical Analysis
Student's t-test was used for statistical analysis. Results with a p-value< 0.05 were considered
significant.
Results
MGL recognises CD45RA on human Treg cells and reduces their
suppressive activity
Tregs were isolated from PBMCs and characterised as shown in Fig 1A. After purification, we
obtained 92% of Tregs (CD4+CD25+FOXP3+) of which 70% were positive for CD45RA.
MGL binding to CD45RA expressed by Treg cells was performed using a recombinant pro-
tein of MGL (rhMGL-Fc). rhMGL-Fc was made up of the extracellular domain of MGL fused
to Fc domain of a human IgG1. We observed that MGL specifically bound Tregs on their sur-
face (65%) and this interaction was abrogated when the GalNAc monosaccharide was incu-
bated with rhMGL-Fc before binding (Fig 1B). Moreover, no Fc receptor (FcRs) expression
was detected on Tregs, thus excluding the Fc portion of rhMGL-Fc as a participatory binding
site (S1 Fig).
To understand if CD45RA was the unique MGL binder, we immunoprecipitated a Treg
lysate with rhMGL-Fc. The immunoprecipitate was then analysed by western blot through
probing of the blot with anti-CD45RA antibody and rhMGL-Fc (Fig 1C). When the membrane
was incubated with the antibody, a line corresponding to CD45RA molecule (220 KDa) was
observed. The same result was obtained using rhMGL-Fc to probe the blot. These data under-
line that CD45RA is the exclusive binder of MGL.
To study the effects of MGL binding on Treg activity, three independent immunosuppres-
sion assays were performed (Fig 1D). As expected, CD4+CD25- T cells alone had maximum
proliferative capacity (100%) after stimulation with anti-CD3 and anti-CD28 antibodies, while
Tregs were anergic (8% proliferation) also after the stimulation with rhMGL-Fc (9,5%). Con-
versely, purified Tregs were able to inhibit CD4+CD25- T cell proliferation, reducing their pro-
liferative capacity from 100% to 60% (p<0.05). The proliferation of T cells was restored and
increased from 60% to 90% (p<0.05) when rhMGL-Fc was added to the culture, suggesting
that MGL-CD45RA interaction significantly modulates Treg function, reducing their immune
suppression activity. Similar results were obtained in presence of antigen specific T cells (Fig
1E). Flu-enriched-CD8+ T cells, obtained from three healthy donors, were stimulated with
autologous mDCs pulsed with HLAI-A2 restricted Flu peptide (GILGFVFTL) in presence or
not of Treg±rhMGL-Fc. CD8+ T-cell activation was measured as IFN-γ production by ELISpot
assay. Results indicated that mDCs induced a strong IFN-γ release when co-cultured with
autologous CD8+ T-cells. The IFN-γ significantly decreased when Treg were added to the cul-
ture (p<0.01), while its production was restored when Treg were stimulated with rhMGL-Fc
(p<0.01).
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Fig 1. MGL recognises CD45RA on human Tregs andmodulates their suppressive capacity. (A) Flow
cytometry analysis of purified Treg stained with anti- CD4, CD25, FOXP3 and CD45RA antibodies. (B)
Competition studies of rhMGL-Fc binding to CD45RA expressed by Tregs using GalNAc polymer. Filled
histograms represent the untreated Tregs, while the open histograms show Tregs treated with rhMGL-Fc or
rhMGL-Fc+GalNAc. (C) Western blot analysis of Treg lysate immunoprecipitated with rhMGL-Fc. Samples
were run in 4–12% SDS-PAGE gel and were analysed with anti-CD45RA and rhMGL-Fc. These results are
representative of one donor out of three. (D) Immunosuppression capacity of Tregs alone and Tregs treated
with rhMGL-Fc after four days of co-culture with CD4+ CD25- T cells (ratio 1:5, Treg:CD4+CD25- T cells), in
presence of anti-CD3 and anti-CD28. (E) IFNγ spots produced by CD8+ T cells (5×104/well) stimulated with
mDCs in presence or not of Tregs ± rhMGL. The results correspond with the mean of three independent
experiments ± standard deviation (SD). * corresponds to p<0.05 and ** to p<0.01.
doi:10.1371/journal.pone.0132617.g001
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Foxp3methylation is up regulated after MGL triggering
The development and immunosuppressive function of Tregs are regulated by the transcrip-
tional factor FOXP3 [13]. The mechanism maintaining stable Foxp3 expression in Tregs
requires demethylation of the Treg specific demethylated region (TSDR) [14]. Therefore,
increased methylation of this region reduces Foxp3 transcription, impairing Treg function. To
evaluate whether changes in Foxp3 gene profiling could account for the decreased immunosup-
pressive activity of Tregs upon MGL-CD45RA interaction, we examined the methylation status
of CpG sites in TSDR. Tregs alone and Tregs after rhMGL-Fc triggering were lysed for cDNA
isolation and analysis. The results in Fig 2A show that the MGL binding on Tregs induced a
significant increase of Foxp3methylation (p<0.01). In fact, in unstimulated Tregs, Foxp3
methylation was 42%, while after MGL-CD45RA interaction, Foxp3methylation became sig-
nificantly higher (50%; p<0.01).
Concurrently, Treg phenotype was monitored comparing Tregs treated with rhMGL-Fc to
untreated Tregs. Tregs isolated from five healthy donors were characterised for the expression
of CD4, CD25, CD45RA and FOXP3. In accordance with the data of Foxp3methylation, results
Fig 2. Binding of rhMGL-Fc to Tregs increases Foxp3methylation and downregulates TCR signalling.
(A) Percentage of Foxp3methylation (TSDR region) of Treg cells alone or after treatment with rhMGL-Fc. The
results correspond to the mean values obtained from three donors ± SD. (B) MFI values of FOXP3
expression of Tregs alone or after treatment with rhMGL-Fc stimulated with anti-CD3. The results correspond
with the mean of three independent experiments ± SD. (C) Western blot analysis of Treg lysates with or
without the treatment of rhMGL-Fc (left). Samples were analysed for pLck (Tyr 505), pLck (Tyr 394) and Zap-
70. β-actin was used as a loading control. Proteins were resolved in 4–12% SDS-PAGE gel. Densitometric
evaluation of the Lck-p505, Lck p-394, Zap-70 signals normalized to the levels of β-Actin (right). These
results are representative of one donor out of three. **Corresponds to p<0.01.
doi:10.1371/journal.pone.0132617.g002
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show that MGL-CD45RA interaction also induced a reduction of FOXP3 expression (Fig 2B),
although this modification was not statistically significant. CD4, CD25 and CD45RA were not
modulated (data not shown).
rhMGL-Fc-CD45RA interaction downregulates CD45 phosphatase
activity
CD45 affects cellular responses by controlling the threshold of sensitivity to external stimuli.
Therefore, to investigate whether MGL binding triggers changes in CD45RA intracellular sig-
nalling, we analysed the phosphatase activity of this receptor. Tregs alone and Tregs stimulated
with rhMGL-Fc were lysed and probed with anti-pLck and anti-Zap-70 antibodies by western
blot (Fig 2C). When CD45 dephosphorylates the negative regulatory tyrosine residue (Y505)
on the protein kinase Lck, this kinase is activated thus triggering the TCR signalling. Reduced
CD45 phosphatase activity after MGL-CD45RA interaction led to enhanced phosphorylation
of Y505, thus decreasing Lck activity. Our results indicated that the binding of MGL to
CD45RA induced a decrease in CD45 phosphatase activity with changes in Lck phosphoryla-
tion. After MGL-CD45RA interaction, Tregs exhibited strong phosphorylation of the Lck Y505
negative regulator, much higher than Tregs alone. Conversely, Tregs alone had Lck phosphory-
lated on Y394, the positive regulatory tyrosine residue. Moreover, because the activation of Lck
challenges the induction of TCR signalling, we analysed the activation of Zap-70. When Treg
cells were treated with rhMGL-Fc, Zap-70 resulted very weak. Instead, Tregs alone showed a
strong activation of Zap-70 (Fig 2C). These data suggested that MGL-CD45 interaction modu-
lates CD45 activity, switching the phosphorylation of Lck on negative residue Y505 and nega-
tively influencing TCR signalling.
MGL binding reduces immunosuppressive cytokines production but
does not significantly affect Treg cell death
We also investigated whether the reduced Treg suppression observed might be attributed to a
conversion toward another specific phenotype (Th1, Th2, and Th17). cDNA isolated by Tregs
alone and Tregs treated with rhMGL-Fc were analysed by RT-PCR for the expression of T-bet,
GATA-3 and RORγt, which are the transcription factors responsible for Th1, Th2 and Th17
cell commitment, respectively. We observed no significant differences between Tregs alone and
Tregs after CD45RA stimulation, suggesting that MGL triggering did not favour the switching
of Treg cells toward a specific Th lineage (Fig 3A).
To confirm these data the production of IL-10, IL-4, IFN-γ and IL-17 by Treg cells was ana-
lysed. Tregs treated with rhMGL-Fc significantly reduced the secretion of IL-10 and IFN-γ
(p<0.05; Fig 3B), while no difference in IL-4 and IL-17 production was observed.
Finally, we examined whether MGL-CD45RA interaction induced apoptosis of Treg cells.
After 48 h of stimulation with anti-CD3 antibody in the presence of rhMGL-Fc, Tregs were
stained with Annexin V and PI. We observed a trend showing an increase in cell death after
triggering with rhMGL-Fc (-MGL vs. +MGL, 35% vs. 39%), although this result was not statis-
tically significant (Fig 3C).
Discussion
Treg-mediated immunosuppression is one of the crucial tumour immune-evasion mechanisms
and represents the main obstacle of successful tumour immunotherapy. Tregs are physiologi-
cally designed to prevent autoimmune diseases by maintaining self-tolerance. These cells are
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able to inhibit the anti-tumour function of specific T cells; in fact their presence in tumour is
directly related to poor prognosis [15].
Due to their important role involved in tumour progression, several strategies are under
investigation to either manipulate the immune system to block the activities of suppressor cells
or antagonise molecules or receptors involved in this process. These approaches are aimed to
revert immunosuppression alone or in combination with molecules that target negative/posi-
tive T receptors, cancer vaccines or traditional chemotherapy [16, 17].
In this work, we demonstrate, for the first time, the role of the C-type lectin MGL in the
modulation of Treg functions via CD45RA. In our previous studies, we have shown the impor-
tant role of this receptor in the tumour-host dynamic interactions [11, 12]. We have proposed
MGL as an optimal candidate receptor for DC-based immunotherapy due to the high plasticity
and the capacity to modulate the immune response combined with the ability to endocytose
and process GalNAc-carrying antigens. In this study, we show that MGL interacts with Tregs
and regulates their functions through the binding to the CD45RA receptor. MGL specifically
binds Tregs, shown in competition studies with the GalNAc where binding is abolished, and
selectively recognises CD45RA on Treg cell surfaces, as shown by immunoprecipitation stud-
ies. In fact, CD45RA is the only molecule immunoprecipitated (220 KDa) by rhMGL, as shown
by probing with anti-CD45RA antibody and with rhMGL. Previous studies have described that
MGL, through the interaction of CD45, negatively regulates the activity of effector T cells
(CD45RA+CD45RO-), decreasing T cell proliferation and increasing T cell death [9]. It is well
known that CD45 represents a key molecule fine-tuning T cell-function. The engagement of
Fig 3. MGL-CD45RA interaction reduces immunosuppressive cytokine production. (A) Real-time PCR analysis of T-bet, RORγT and GATA3 genes in
Tregs alone (grey columns) or after treatment with rhMGL-Fc (black columns). Relative gene expression was normalized with B2M and RLP0 gene
expression levels. The results correspond to the mean value ± SD of three donors. (B) Intracellular staining of IL-10, IL-4, IFN-γ and IL-17 in Tregs alone
(gray columns) or after treatment with rhMGL-Fc (black columns). The results correspond to the mean obtained from ten independent experiments ± SD. (C)
Flow cytometry analysis of Tregs cultured with or without rhMGL-Fc and soluble anti-CD3. Quantification of cell death was performed using annexin-V-FITC
and propidium iodide-PE. The results correspond to the mean value ± SD of three donors. *Corresponds to p<0.05.
doi:10.1371/journal.pone.0132617.g003
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CD45 through MoAbs has been successfully employed to modulate T cell responses inducing
tolerance in vivo and in vitro transplant models [18, 19].
T cells can express different isoforms of CD45 such as CD45RA and RO, according to the
activation status of the cells. In Treg subpopulations, CD45RA expression is associated with
the unique Treg subset able to maintain, in vitro, the suppressive activity given by a stable
expression of FOXP3 [7, 8]. Employing a recombinant MGL molecule and purified Treg cells
expressing CD45RA, we have observed that the binding between MGL and CD45RA expressed
by CD45RA+FOXP3+ Tregs reduces the suppressive activity of this cell subset restoring the
proliferative capacity of T cells.
The crucial role of CD45 protein tyrosine phosphatase promoting T cell activation and
development [20] is primarily attributed to the positive regulatory role of CD45 in fostering
the activity of Lck, a Src family kinase. In fact, Lck helps initiate TCR-mediated signal trans-
duction pathways by inducing tyrosine phosphorylation of CD3/z ITAM residues as well as
association and activation of the Zap-70 tyrosine kinase [21]. The CD45-MGL interaction also
leads to Lck inactivation within the Treg subpopulation, as described for the effector counter-
part [9]. Moreover, we show that this phospho-signalling leads to inactivation of Zap-70,
resulting in the TCR signalling block.
The decrease of Treg suppressive activity did not correlate with cell death. Although we
detected CD45-dependent apoptosis in human Treg after MGL binding, this was not signifi-
cant. This result is in agreement with what was described in Treg mouse models in which apo-
ptosis did not correlate with the abrogation of Treg suppression activity upon cross-linking of
CD45RO with a specific MoAb [22].
It is well known that stable expression of FOXP3 is an essential prerequisite for the mainte-
nance of suppressive properties of Tregs. Stable Foxp3 expression is associated with selective
demethylation of an evolutionarily conserved element within the Foxp3 locus named TSDR
[14] although a direct correlation between the degree of TSDRmethylation and protein level of
FOXP3 was not observed [23]. We found that MGL-CD45RA cross-linking significantly
increased the methylation status of TSDR, thus reducing the immunosuppressive activity of
Tregs, while only a trend toward the decrease of FOXP3 protein was observed.
Several studies provide evidence that Treg differentiation is an irreversible process. How-
ever, more recently data indicates that Treg cells retain developmental plasticity, namely the
capacity to be reprogrammed into various Th cell subsets depending on the extrinsic stimuli
used [24, 25]. Treg stimulated with MGL lose part of their suppressive activity, but
CD45RA-MGL interaction was not sufficient to favour the switching of Tregs toward a specific
Th lineage. We observed no increase of the specific transcription factors that characterised the
Th1, Th2 and Th17 lineage (Tbet, GATA3 and RORγt, respectively) and no increase in the pro-
duction of IL-4 and IL-17. Moreover, we detected a significant decrease in IL-10 and IFN-γ.
Tregs are able to produce several type of cytokines. IL-10 represents the cytokine required for
their immunosuppressive activity [26]. Additionally, CD4+CD127lowCD25+ Tregs expressing
high levels of FOXP3 with a high suppressive capacity produced IFN-γ. The decrease in IL-10
and IFN-γ could account for the reduction of Treg suppressive activity observed in our in vitro
system.
In this study, we describe for the first time a novel mechanism whereby Treg functionality
can be overcome, depending on the interaction between CD45RA and the C-type lectin MGL.
This interaction is able to modify the epigenetic signature of Foxp3 and signalling pathways,
thus reducing the immunosuppressive potential of Treg CD45RA+FOXP3+, i.e., a lower pro-
duction of immunosuppressive cytokines and restoration of effector T cell proliferation.
We are currently investigating the MGL-CD45RA interaction between DCs and Tregs to
better understand the relevance of this interaction in an in vitro cell system.
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The reported results herein strengthen the role of MGL as immunomodulator of the tumour
microenvironment able to interfere with Treg functions in addition to mediate glycoantigen
up-take and DC activation. Therefore, these results strongly suggest its employment in the
design of anticancer vaccines.
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